- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Brian Lehman, MBA, MHA, RPh: Progress for Biosimilars in 2019
Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses positive developments for biosimilars over the past year.
Transcript
Absolutely. So within the biosimilar marketplace, it's projected to be $54 billion in savings over 10 years, and what we've seen, for example, is biosimilars have had some of those savings. Zarxio, filgrastim, was one of those products that in less than 2 years actually has saved over $500 million for patients. The FDA has been active in approving biosimilars. So in 2019 already, 7 products have been approved for now a total of 23 products.* And what also we've seen in 2019 is the FDA is even getting more involved with patient education, and in even moreso with provider education.
*As of the date of filming.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
